The Parkinson’s Progression Markers Initiative (PPMI) is an ongoing longitudinal observational study, launched in 2010, with more than 1,500 participants contributing comprehensive clinical and imaging data and biological samples at 33 clinical sites around the world. Sponsored by The Michael J. Fox Foundation and supported by a number of industry partners, this study has built a robust database and biorepository, which it makes available to the research community to further biomarker discovery and validation and therapeutic development.
- 423 de novo idiopathic PD patients; 196 healthy controls; 64 subjects with scans without evidence of dopaminergic deficit (SWEDDs)
- 65 subjects with Parkinson's risk factors of hyposmia or REM sleep behavior disorder
- 372 LRRK2 mutation carriers; 246 GBA mutation carriers; 27 SNCA mutation carriers (PD and unaffected)
- Clinical: motor, non-motor (cognitive, neurobehavioral, neuropsychological, autonomic, olfaction, sleep)
- Imaging: fMRI, DaTSCAN SPECT, DTI, AV-133
- Biologic: e.g. spinal fluid alpha-synuclein, amyloid-beta, tau, phosphorylated tau levels
- Genetic: SNP genotyping, whole exome sequencing, whole genome sequencing data, transcriptomics, DNA methylation
Associated Data Distribution Platforms
Parkinson's Progression Markers Initiative Data Repository
Clinical, imaging, biologic, and genetic data collected through PPMI are available in the Parkinson’s Progression Markers Initiative (PPMI) Data Repository, a robust data resource widely used to assist in the design of Parkinson's clinical trials.
AMP PD Knowledge Platform
Clinical and genetic data collected through PPMI are also harmonized with data from several other large studies and made available through the Accelerating Medicines Partnership Parkinson’s disease (AMP PD) Knowledge Platform.